论文部分内容阅读
对24例AMI后未用过能影响PG代谢药物的患者、17例AMI后用过能影响PG代谢药物的患者及45例健康正常人,分别测定其周围静脉血浆TXB_2浓度,见前组明显高于后两组。同时测定28例健康正常人及18例AMI后未用过能影响PG代谢药物的患者的静脉血浆TXB_2、6-酮-PGF_(1α)T/6比值,见两组6-酮-PGF_(1α)值无显著差异,而正常人T/6比值较低。因此认为,对AMI患者测定TXB_2及T/6比值,可能为临床测AMI患者发病提供有参考价值的依据。
Twenty-four patients with AMI who had not been able to influence the metabolism of PG metabolites, 17 patients with AMI who could affect the metabolism of PG drugs and 45 healthy controls were measured peripheral venous plasma TXB_2 concentration, After two groups. The levels of TXB_2.6-keto-PGF_ (1α) T / 6 in venous plasma of 28 patients with healthy controls and 18 patients without AMI after using AMI were determined. Six groups of 6-keto-PGF_ (1α ) Values were not significantly different, while the normal T / 6 ratio was lower. Therefore, the determination of TXB_2 and T / 6 ratio in patients with AMI may provide a reference for the clinical diagnosis of AMI patients.